HomeCompareCPPCY vs PFE

CPPCY vs PFE: Dividend Comparison 2026

CPPCY yields 3.14% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $23.9K in total portfolio value· pulled ahead in Year 9
10 years
CPPCY
CPPCY
● Live price
3.14%
Share price
$13.38
Annual div
$0.42
5Y div CAGR
3.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$585.80
Full CPPCY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CPPCY vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCPPCYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CPPCY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CPPCY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CPPCY
Annual income on $10K today (after 15% tax)
$266.82/yr
After 10yr DRIP, annual income (after tax)
$497.93/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,821.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CPPCY + PFE for your $10,000?

CPPCY: 50%PFE: 50%
100% PFE50/50100% CPPCY
Portfolio after 10yr
$37.6K
Annual income
$13,422.26/yr
Blended yield
35.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CPPCY
No analyst data
Altman Z
1.6
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CPPCY buys
0
PFE buys
0
No recent congressional trades found for CPPCY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCPPCYPFE
Forward yield3.14%6.13%
Annual dividend / share$0.42$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR3.9%13.2%
Portfolio after 10y$25.6K$49.6K
Annual income after 10y$585.80$26,258.71
Total dividends collected$4.5K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CPPCY vs PFE ($10,000, DRIP)

YearCPPCY PortfolioCPPCY Income/yrPFE PortfolioPFE Income/yrGap
1$11,026$326.14$9,153$693.39+$1.9KCPPCY
2$12,147$349.19$8,593$849.25+$3.6KCPPCY
3$13,371$373.55$8,336$1,066.78+$5.0KCPPCY
4$14,706$399.27$8,437$1,384.80+$6.3KCPPCY
5$16,162$426.42$9,013$1,875.40+$7.1KCPPCY
6$17,749$455.06$10,306$2,680.72+$7.4KCPPCY
7$19,476$485.25$12,820$4,101.38+$6.7KCPPCY
8$21,357$517.05$17,673$6,826.70+$3.7KCPPCY
9← crossover$23,402$550.55$27,543$12,591.86$4.1KPFE
10$25,626$585.80$49,560$26,258.71$23.9KPFE

CPPCY vs PFE: Complete Analysis 2026

CPPCYStock

CP ALL Public Company Limited, together with its subsidiaries, operates and franchises convenience stores under the 7-Eleven name to other retailers primarily in Thailand. It operates through three segments: Wholesale Business, Retail Business, and Management of Rental Spaces in Shopping Centers. The Wholesale Business segment engages in import, export, and distribution of frozen and chilled food with delivery services and focuses on selling consumer products, including fresh food, dry food, and consumer products under Makro brand. Its Retail Business segment is involved in domestic supply chain, distribution system, logistics network, and brand equity businesses. This segment also sells its products under various domestic, international, and small and medium enterprises brands. The company's Management of Rental Spaces in Shopping Centers segment manages buildings and retail spaces in shopping malls. In addition, the company is involved in sale and maintenance of retail equipment; cash and carry, catalog, and e-commerce businesses; marketing and advertising activities; provision of information technology and research and development services, as well as engaged in bill payment collection, life insurance, and non-life insurance broker business. Further, the company offers educational institution, training, business seminar services, as well as healthcare and medical specialist's consultation services. As of December 31, 2021, CP ALL Public Company Limited operated 13,134 stores. The company was formerly known as C.P. Seven Eleven Public Company Limited. CP ALL Public Company Limited was founded in 1988 and is headquartered in Bangkok, Thailand.

Full CPPCY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CPPCY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CPPCY vs SCHDCPPCY vs JEPICPPCY vs OCPPCY vs KOCPPCY vs MAINCPPCY vs JNJCPPCY vs MRKCPPCY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.